ACT Genomics is honoured to collaborate with AstraZeneca Singapore for both somatic and germline genetic testing of BRCA in patients with ovarian cancer, using the advanced next generation sequencing (NGS) technology. International guidelines such as those from ESMO, ASCO and NCCN recommend BRCA testing, which will provide patients and doctors with important information on disease prognosis and may improve treatment decisions.

With the advancements in precision medicine, patient care can now be managed better. ACT Genomics is proud to be part of patients’ journey and together we “Turn Genomics into Action."